beta-2 Microglobulin anticorps (AA 21-119)

N° du produit ABIN5776062

Cet anticorps Souris Monoclonal détecte spécifiquement beta-2 Microglobulin dans WB, FACS, ELISA, IF et ICC. Il présente une réactivité envers Humain.

Aperçu rapide pour beta-2 Microglobulin anticorps (AA 21-119) (ABIN5776062)

Antigène: beta-2 Microglobulin (B2M) (beta-2-Microglobulin (B2M))

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp beta-2 Microglobulin est non-conjugé

Application: Western Blotting (WB), Flow Cytometry (FACS), ELISA, Immunofluorescence (IF), Immunocytochemistry (ICC)

Clone: AT101F10

Détail du produit anti-beta-2 Microglobulin anticorps

Épitope: AA 21-119

Immunogène: Recombinant human B2M (21-119aa) purified from E. coli

Isotype: IgG2b kappa

Information d'application

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 1 mg/mL

Stock: 4 °C,-20 °C,-80 °C

Stockage commentaire: Can be stored at +2°C to +8°C for 1 week. For long term storage, aliquot and store at -20°C to -80°C. Avoid repeated freezing and thawing cycles.

Détails sur beta-2 Microglobulin

Antigène: beta-2 Microglobulin (B2M) (beta-2-Microglobulin (B2M))

Autre désignation: beta 2-Microglobulin/B2M

Sujet: Beta2 microglobulin, also known as B2M, is a component of MHC class I molecules, Involved in the presentation of peptide antigens to the immune system. B2M is a protein found on the surface of many cells and plentiful on the surface of white blood cells. Increased production or destruction of these cells causes B2M levels in the blood to increase. This increase is seen in people with cancers involving white blood cells, but it is particularly meaningful in people newly diagnosed with multiple myeloma. Multiple myeloma is a malignancy (cancer) of a certain kind of white blood cell, called a plasma cell. B2M Testing is done primarily when evaluating a person for certain kinds of cancer affecting white blood cells including chronic lymphocytic leukemia, non-Hodgkin's lymphoma, and multiple myeloma or kidney disease.

NCBI Accession: NP_004039

Pathways: TCR Signaling, Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process